Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 856632 | ISIN: US5745991068 | Ticker-Symbol: MSQ
Frankfurt
06.06.25 | 08:14
55,14 Euro
-0,07 % -0,04
Branche
Bau/Infrastruktur
Aktienmarkt
S&P 500
1-Jahres-Chart
MASCO CORPORATION Chart 1 Jahr
5-Tage-Chart
MASCO CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
55,3055,6406.06.
55,1655,7206.06.
ACCESS Newswire
205 Leser
Artikel bewerten:
(1)

Masco Group, a Global Leader in Engineering Technologies and Services Solutions for Biopharmaceutical Manufacturing, Expands Its U.S. Presence and Process Portfolio With the Acquisition of Techniserv

MILAN, IT / ACCESS Newswire / June 6, 2025 / Masco Group is proud to announce the acquisition of Techniserv, Inc., a U.S.-based expert in bioreactor technology and process systems. This strategic move significantly strengthens Masco Group's presence in the United States and enhances its capabilities across both upstream and downstream bioprocessing.

Techniserv will continue to operate under its current leadership team and will become part of Masco Group's Process Business Unit, ensuring continuity for its clients, employees, and suppliers while benefiting from Masco Group's global scale, engineering depth, and operational resources.

"The addition of Techniserv is a natural extension of our continued growth strategy," said Luca Borella, CEO of Masco Group. "It allows us to provide local integrated process solutions in the U.S. and other key markets - including bioreactors and all supporting process equipment, high-purity utilities, automation, and CQV."

"This acquisition significantly increases both the capacity and the range of technologies we can offer our clients and A&E partners," said Richard Keays, CEO of Masco Group's Process Business Unit. "With Techniserv joining Olsa and BCD, we now manufacture process equipment in Italy, Ireland and the United States. Just as importantly, Techniserv brings a strong U.S.-based service team, giving us local presence and the ability to respond to our clients faster and more effectively. Together, we are now among the largest international players in upstream and downstream processing, with the scale and expertise to support biopharma manufacturers globally."

"Joining Masco Group and Process BU and taking advantage of Masco Group's engineering, manufacturing, and technical commercial capabilities is a great opportunity for Techniserv and our customers," said Brandon Kotsko, President of Techniserv. "Our team, dedicated to delivering high-quality systems, can now offer more and leverage Masco Group's existing engineering and manufacturing capabilities to better serve our clients. This partnership will accelerate our ability to grow and innovate - both in the U.S. and overseas."

Masco Group and Techniserv remain fully committed to supporting all existing and new projects and clients. In the coming weeks, both companies will engage directly with customers to share more about their combined capabilities and future plans.

Masco Group
Masco Group is a multicompetent team of specialist companies - including Stilmas, Olsa, KeyPlants, BCD, DOC, Masco Group Automation, MascoLab, and VILS - delivering progressive engineering and cutting-edge solutions for life science manufacturing. We deliver innovative design and manufacturing of facility modules and high-purity process systems, advanced process and automation engineering, expert project management, and strong capabilities in conceptual design. We also ensure strict compliance through deep qualification, validation, regulatory knowledge and laboratory services. With a presence across five continents and a commitment to technical excellence, Masco Group delivers innovation that powers the future of pharmaceutical manufacturing.

Techniserv, Inc.
Founded in 1982, Techniserv is a U.S.-based provider of bioreactor and process systems serving the pharmaceutical, biotech, food, and fine chemical industries. With a 62,000 sq. ft. facility in Pennsylvania and decades of engineering expertise, Techniserv offers complete solutions from design through fabrication, automation, and qualification, being reference partner to the main bio-pharma companies in U.S.

Contact Information
Christian Larsen
VP, Group Marketing
c.larsen@mascogroup.com
+4530949254

.

SOURCE: Masco Group



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/masco-group-a-global-leader-in-engineering-technologies-and-services-1035874

© 2025 ACCESS Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.